Predicted protein targets (top 2)
Click a target to see other patent compounds predicted against it — the reverse direction, in place.
Similar compounds — the chemically nearest patent molecules
Nearest neighbours by Morgan-fingerprint cosine across the patent-compound collection, with each neighbour's top predicted target and the predicted targets it shares with this molecule.
| Compound | similarity | top predicted | shared targets | |
|---|---|---|---|---|
| SCHEMBL5179155 | 0.90 | CETP (0.47) | CETP | |
| SCHEMBL760742 | 0.86 | TRPM8 (0.41) | CETP | |
| SCHEMBL12710497 | 0.85 | CETP (0.39) | CETP | |
| SCHEMBL10684647 | 0.80 | PIM1 (0.41) | CETP | |
| SCHEMBL5670119 | 0.78 | CETP (0.54) | CETP | |
| SCHEMBL498326 | 0.78 | PIM1 (0.48) | CETP | |
| SCHEMBL4550413 | 0.77 | CETP (0.44) | CETP | |
| SCHEMBL24588079 | 0.76 | TRPM8 (0.41) | CETP | |
| Hydrochloric Acid SCHEMBL2714066 | 0.76 | CETP (0.43) | CETP | |
| SCHEMBL6774609 | 0.76 | CETP (0.42) | CETP |
Similarity is cosine over the 2,048-bit Morgan fingerprint (≈ Tanimoto). Identical fingerprints score 1.00.
Patent provenance — the patents this molecule appears in, and who filed them
Claimed or disclosed in 7 patents. claimed = in the patent's claims; disclosed = body only.
| Patent | Title | Assignee | Published | Priority | Filing | Country | Status |
|---|---|---|---|---|---|---|---|
| EP-1589000-A2 | (R)-Chiral halogenated 1-substitutedamino-(N+1)-alkanols useful for inhibiting cholesteryl ester transfer protein activity | Monsanto Company (US) | 2005-10-26 | — | — | EP | disclosed |
| EP-1115695-B1 | (R)-CHIRAL HALOGENATED 1-SUBSTITUTEDAMINO-(N+1)-ALKANOLS USEFUL FOR INHIBITING CHOLESTERYL ESTER TRANSFER PROTEIN ACTIVITY | MONSANTO CO (US) | 2005-06-01 | — | — | EP | disclosed |
| US-20050043294-A1 | (R)-chiral halogenated substituted fused heterocyclic amino compounds useful for inhibiting cholesterol ester transfer protein activity | PFIZER INC | 2005-02-24 | — | — | US | disclosed |
| US-6683113-B2 | TREATING ATHEROSCLEROSIS AND OTHER CORONARY ARTERY DISEASES | PHARMACIA CORPORATION | 2004-01-27 | — | — | US | disclosed |
| US-20030078264-A1 | (R)-chiral halogenated substituted N,N-bis-benzyl aminoalcohol compounds useful for inhibiting cholesteryl ester transfer protein activity | SIKORSKI JAMES A (US) | 2003-04-24 | — | — | US | disclosed |
| US-20030040545-A1 | (R)-Chiral halogenated substituted fused heterocyclic amino compounds useful for inhibiting cholesteryl ester transfer protein activity | SIKORSKI JAMES A (US) | 2003-02-27 | — | — | US | disclosed |
| US-6521607-B1 | Preventing coronary artery disease | PHARMACIA CORPORATION | 2003-02-18 | — | — | US | disclosed |
Patent text — is the patent's own abstract consistent with the prediction?
For each of this compound's patents that has machine-readable text (3 of them — usually the abstract, not the full specification), we ask MedCPT which protein the text reads most about, and where the chemistry-predicted target lands among 4885 human targets. A high rank means the patent's own wording is consistent with the prediction — a weak, independent signal, not proof of activity.
| Patent | Title | Text reads most about | Predicted target · text-rank |
|---|---|---|---|
| US-20050043294-A1 | (R)-chiral halogenated substituted fused heterocyclic amino compounds useful for inhibiting cholesterol ester transfer protein activity | CETP, DBI, MTTP | CETP 1/4885SCN9A 2570/4885 |
| US-20030078264-A1 | (R)-chiral halogenated substituted N,N-bis-benzyl aminoalcohol compounds useful for inhibiting cholesteryl ester transfer protein activity | CETP, DBI, MTTP | CETP 1/4885SCN9A 1777/4885 |
| US-20030040545-A1 | (R)-Chiral halogenated substituted fused heterocyclic amino compounds useful for inhibiting cholesteryl ester transfer protein activity | CETP, MTTP, PLTP | CETP 1/4885SCN9A 3215/4885 |
“Text reads most about” is the patent abstract's nearest protein in MedCPT space (background-debiased). Only ~1.4% of patents have machine-readable text, so most compounds won't have this panel.